Schwartz was a principal investigator in a number of early-stage clinical trials for retinal diseases, including the initial studies for ranibizumab (Lucentis) – an injectable drug that is now a common treatment for wet age-related macular degeneration. Schwartz leads clinical trials of novel cell therapies and drugs to treat blinding eye diseases. He aims to translate basic biological discoveries into new treatment strategies, and to develop and evaluate novel medical device technologies, imaging technologies, surgical equipment (including surgical robots) and drug delivery systems. Steven Schwartz, M.D., is an ophthalmologist whose primary research areas include early diagnosis and treatment of diseases such as macular degeneration, retinopathy of prematurity and diabetic eye disease.